Exelixis' Lead Cancer Treatment Delivers Another Surprise, Though Analyst Finds Commercial Opportunity In Pancreatic Neuroendocrine Modest
Portfolio Pulse from Vandana Singh
Exelixis Inc's (EXEL) phase 3 CABINET pivotal trial for its lead cancer treatment, Cabometyx, has been recommended to stop early due to significant improvement in efficacy. The trial was evaluating Cabometyx against a placebo in patients with advanced pancreatic neuroendocrine tumors. William Blair analysts have reiterated their Outperform rating for EXEL, despite uncertainties surrounding the market exclusivity of Cabometyx, which is projected until 2030.
August 24, 2023 | 6:46 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Novartis's Lutathera, a lutetium-177 radiolabeled SSTR analog, is mentioned as a good proxy for the study population of Exelixis's trial.
The mention of Novartis's Lutathera in relation to Exelixis's trial does not directly impact Novartis's stock, but it does highlight the drug's relevance in the field.
CONFIDENCE 80
IMPORTANCE 50
RELEVANCE 50
POSITIVE IMPACT
Exelixis's phase 3 trial for Cabometyx shows significant efficacy improvement, which could boost investor confidence.
The positive results from the phase 3 trial of Cabometyx could increase investor confidence in Exelixis, potentially leading to a rise in the company's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100